Related Experiment Video
Updated: Apr 27, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
Tumor necrosis factor inhibitors in psoriasis: an update
Francisco A Kerdel1, Bruce E Strober2
1Professor of Dermatology and Vice Chairman, Florida International University, Miami, Florida.
Abstract:
Three inhibitors of tumor necrosis factor (TNF) currently are approved for the treatment of psoriasis: etanercept, infliximab, and adalimumab. The other two TNF inhibitors, golimumab and certolizumab pegol, have shown efficacy against plaque psoriasis in clinical trials of psoriatic arthritis (PsA). This article reviews the most recent evidence on the efficacy and safety of the TNF inhibitors in psoriasis, with special attention to preventing and managing immunogenicity.
More Related Videos
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Tumor Immunotherapy
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Inflammatory Bowel Disease II: Ulcerative Colitis
The Tumor Microenvironment

